Human testing can only begin after a pharmaceutical company submits an Investigational New Drug (IND) application, detailing the drug’s profile—such as toxicology reports, manufacturing procedures and clinical trial protocols—using FDA-approved templates, all within carefully coordinated timelines.
Failure to submit the IND application correctly and on time can result in rejection, delays and costly resubmissions, ultimately postponing the availability of potentially life-changing treatments for patients in need.
Enter Quantum Regulatory Solutions, a boutique consulting firm that specializes in helping pharmaceutical and biotech companies prepare and submit regulatory applications to the FDA for clinical trial applications and marketing approvals. Quantum uses DXC’s ToolBox Pharma Edition*, a regulatory information management (RIM) application that streamlines production of FDA-compliant documents.
*DXC Toolbox Pharma’s latest version [v6.5] uses DXC’s FirstPoint RIM.AI—a cloud-native AI Automation framework—to accelerate regulatory filings by up to 60%.